Aptamers are short oligonucleotides that bind to specific target molecules. They have been
extensively explored in biomedical applications, including biosensing, medical imaging, and …

The combined use of diagnostic and therapeutic radioligands with the same molecular
target, also known as theranostics, enables accurate patient selection, targeted therapy, and …

Fibroblast activation protein (FAP), a fundamental component of the tumor stroma, is
overexpressed in cancer-associated fibroblasts (CAFs). As a promising theranostic probe …

Primary breast neuroendocrine (NE) neoplasms are uncommon, and definitions harbor
controversy. We retrospectively collected 73 triple‐negative breast cancers (TNBC) and …

Simple Summary Peptide receptor radionuclide therapy (PRRT) is a systemic treatment
consisting of the administration of a tumor-targeting radiopharmaceutical into the circulation …

Rationale: This study aimed to assess the safety, efficacy, and survival of 177 Lu-DOTA-EB-
TATE in patients with metastatic neuroendocrine tumors (NETs). Methods: Thirty patients …

Radiopharmaceuticals are essential components of nuclear medicine and serve as one of
the cornerstones of molecular imaging and precision medicine. They provide new means …

Abstract Purpose of Review Peptide receptor radionuclide therapy (PRRT) with [177 Lu-
DOTA 0, Tyr 3] octreotate is an effective and safe second-or third-line treatment option for …

A growing body of literature reports on the combined use of peptide receptor radionuclide
therapy (PRRT) with other anti-tumuor therapies in order to anticipate synergistic effects with …

Peptide receptor radionuclide therapy (PRRT) is an emerging approach for patients with
unresectable or metastatic tumors. Our previously optimized RGD peptide (3PRGD2) has …